Immatics N.V.: Trading Below Cash, But Not Without Reason
Source: SeekingAlpha
2025-03-28 13:02:08 ET
Summary
- Immatics' lead asset, IMA203, shows promising early data with a 57% ORR in heavily pretreated patients, but toxicity concerns remain.
- Financially, IMTX has a $540mn market cap and $628mn cash, but negative enterprise value due to early-stage data and long catalyst desert.
- Phase 3 trial for IMA203 will produce interim data in early 2026, with no clear topline data timeline, creating uncertainty.
- Despite early signs of activity, I recommend waiting for phase 3 data before considering an investment due to small market size and emerging competition.
...
Read the full article on Seeking Alpha
For further details see:
Immatics N.V.: Trading Below Cash, But Not Without Reason
Immatics N.V.
NASDAQ: IMTX
IMTX Trading
-0.61% G/L:
$11.37 Last:
87,110 Volume:
$11.48 Open:
IMTX Latest News
May 30, 2026 08:00:00 am
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
May 12, 2026 07:00:00 am
Immatics Announces First Quarter 2026 Financial Results and Business Update
IMTX Stock Data
$1,341,978,928
63,814,383
N/A
32
N/A
Biotechnology & Life Sciences
Healthcare
DE
Tbingen
